genedrive plc

genedrive plc designs, develops, and manufactures molecular diagnostics testing equipment for genotyping, pathogen detection, infectious disease detection, and other clinical indications. Its products include the Genedrive system, a rapid nucleic acid thermocycler and fluorescence detection system for qualitative in vitro molecular diagnostic tests, and the Genedrive CYP2C19 ID Kit, a certified test to identify individuals unlikely to respond to the antiplatelet drug Clopidogrel. It also offers the Genedrive MT-RNR1-ID Kit for rapid genetic testing in emergency neonatal care, tests for antibiotic-induced hearing loss in neonates, HCV infection confirmation before drug administration, pathogen detection of biological military threats, and a point-of-care COVID-19 detection system for healthcare, workplace screening, travel requirements, and antigen test confirmation. The company serves the medical, biotechnology, and pharmaceutical industries in the United Kingdom, Europe, the United States, and internationally, and has a collaboration agreement with Thermo Fisher Scientific Inc. to develop a CYP2C19 pharmacogenetic in vitro diagnostic test. Formerly known as Epistem Holdings Plc, it changed its name to genedrive plc in July 2016, was founded in 2000, and is headquartered in Manchester, the United Kingdom.